Bunkerhill Health

The product is AI infrastructure: a platform whose entire function is building, deploying, and governing AI agents, plus the company's own FDA cleared imaging algorithms that run inside it. Remove the AI and nothing remains.

Agents take real actions rather than only surfacing recommendations, and the vendor describes drafting orders for clinician sign off, which is an explicit human in the loop pattern on the clinical side. The company states the platform provides governance, monitoring, and safety capabilities. Held back from A because no published governance framework, escalation policy, or audit documentation was retrieved, and an agent authoring platform pushes oversight design onto the customer, which raises rather than lowers the disclosure bar.

Named institutional deployments at scale, with more than 20 agents reported running simultaneously at UTMB, and specific operational figures including a reported reduction in average specialist wait times of more than 50 percent for a nephrology triage agent. Held back from A because the clinical outcome evidence is presented as individual case narratives, including a coronary calcium detection that preceded a triple bypass, rather than as cohort level published results, and the figures are vendor and customer reported without stated methodology.

The strongest regulatory position among provider side vendors in the index. Multiple FDA clearances on the company's own algorithms, including Bunkerhill Contrast CAC and Contrast AVC, which the company states are the first AI algorithms cleared to detect and quantify coronary artery calcium and aortic valve calcium on contrast enhanced non gated chest CT, alongside earlier non contrast clearances, mitral annular calcification, and bone mineral density. CMS established a national billing code and OPPS payment for algorithmic CAC and AVC analysis effective April 1, 2026. A reimbursement pathway is materially rarer than a clearance and is disclosed precisely.

No public pricing. Contact the vendor. Sold through enterprise agreements with health systems; no rate card published. Note that the CMS billing code for CAC and AVC analysis creates a reimbursement path for certain algorithm use, which is a distinct economic question from platform licensing cost.

Coverage is broad by design, spanning cardiology, nephrology, pulmonary nodule follow up, oncology prior authorization, and registry operations across clinical, operational, and administrative functions. Clearly described, though breadth is a property of the platform model rather than a validated scope, and the axis rewards validated clarity over range.